Literature DB >> 21533727

Migraine with aura: conventional and non-conventional treatments.

Giovanni D'Andrea1, Davide Colavito, Maurizio Dalle Carbonare, Alberta Leon.   

Abstract

Migraine with aura (MwA) is a primary headache that affects up 30% of migraine patients. Although the frequency of MwA attacks is usually low and the majority of migraine sufferers do not need prophylactic treatment(s), same particular patients do. This occurs when the neurological symptoms, that characterize the auras, determine anxiety to the migraine sufferers and when the frequency of MwA attacks is or becomes high. In this study, we review the few therapeutic conventional options specifically devoted to cure MwA attacks present in the literature together with those, recent, non-conventional.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21533727     DOI: 10.1007/s10072-011-0529-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  61 in total

1.  Perfusion weighted imaging during migraine: spontaneous visual aura and headache.

Authors:  M Sanchez del Rio; D Bakker; O Wu; R Agosti; D D Mitsikostas; L Ostergaard; W A Wells; B R Rosen; G Sorensen; M A Moskowitz; F M Cutrer
Journal:  Cephalalgia       Date:  1999-10       Impact factor: 6.292

2.  Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.

Authors:  T J Steiner; L J Findley; A W Yuen
Journal:  Cephalalgia       Date:  1997-04       Impact factor: 6.292

3.  Inhibition of platelet-activating factor receptors in hippocampal plasma membranes attenuates the inflammatory nociceptive response in rats.

Authors:  Lisa A Teather; Veronica M Afonso; Richard J Wurtman
Journal:  Brain Res       Date:  2006-06-13       Impact factor: 3.252

Review 4.  Treatment of migraine with aura: comments and perspectives.

Authors:  G D'Andrea; V Bonavita; A Rigamonti; G Bussone
Journal:  Neurol Sci       Date:  2003-02       Impact factor: 3.307

5.  Lamotrigine in the prophylactic treatment of migraine aura--a pilot study.

Authors:  C Lampl; A Buzath; D Klinger; K Neumann
Journal:  Cephalalgia       Date:  1999-01       Impact factor: 6.292

6.  Platelet glycine, glutamate and aspartate in primary headache.

Authors:  G D'Andrea; A R Cananzi; R Joseph; M Morra; F Zamberlan; F Ferro Milone; S Grunfeld; K M Welch
Journal:  Cephalalgia       Date:  1991-09       Impact factor: 6.292

7.  Classic migraine: effective prophylaxis with metoprolol.

Authors:  P Kangasniemi; A R Andersen; P G Andersson; N E Gilhus; C Hedman; M Hultgren; S Vilming; J Olesen
Journal:  Cephalalgia       Date:  1987-12       Impact factor: 6.292

8.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

9.  Hyperexcitability of the primary somatosensory cortex in migraine--a magnetoencephalographic study.

Authors:  Eberhard Lang; Martin Kaltenhäuser; Bernhard Neundörfer; Sia Seidler
Journal:  Brain       Date:  2004-10-07       Impact factor: 13.501

10.  Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine.

Authors:  J Olesen; B Larsen; M Lauritzen
Journal:  Ann Neurol       Date:  1981-04       Impact factor: 10.422

View more
  7 in total

1.  May a suspicious psychiatric disorder hide sporadic hemiplegic migraine? Genetic test as prompting factor for diagnosis.

Authors:  C Liguori; M Albanese; G Sancesario; A Stefani; M G Marciani; M Pierantozzi
Journal:  Neurol Sci       Date:  2013-02-10       Impact factor: 3.307

Review 2.  Visual Snow: a Potential Cortical Hyperexcitability Syndrome.

Authors:  Alaa Bou Ghannam; Victoria S Pelak
Journal:  Curr Treat Options Neurol       Date:  2017-03       Impact factor: 3.598

Review 3.  OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.

Authors:  James E Frampton
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

4.  OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine.

Authors:  Katherine A Lyseng-Williamson; James E Frampton
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

Review 5.  Migrainous infarction: aspects on risk factors and therapy.

Authors:  Katarina Laurell; Erik Lundström
Journal:  Curr Pain Headache Rep       Date:  2012-06

Review 6.  Involvement of gap junction channels in the pathophysiology of migraine with aura.

Authors:  Denis Sarrouilhe; Catherine Dejean; Marc Mesnil
Journal:  Front Physiol       Date:  2014-02-25       Impact factor: 4.566

7.  Polymorphisms in migraine-associated gene, atp1a2, and ischemic stroke risk in a biracial population: the genetics of early onset stroke study.

Authors:  Andrea M Harriott; Nicole Dueker; Yu-Ching Cheng; Kathleen A Ryan; Jeffrey R O'Connell; O Colin Stine; Patrick F McArdle; Marcella A Wozniak; Barney J Stern; Braxton D Mitchell; Steven J Kittner; John W Cole
Journal:  Springerplus       Date:  2013-02-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.